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Abstract.  Malaria  and  HIV/AIDS  are  among  the  principal  causes  of  morbidity  and  mortality 
worldwide,  particularly  in  resource
international community’s efforts to reduce incidence and prevalence of these diseas
a global public health problem. Clinical manifestations of malaria may be more severe in HIV 
infected patients, which have higher risks of severe malaria and malaria related death. Co
pregnant women, children and international trav
higher risk of clinical complications. However, there is a paucity and conflicting data regarding 
malaria  and  HIV  co-infection,  particularly  on  how  HIV  infection  can  modify  the  response  to 
antimalarial  drugs  and  about  drug
based  combined  regimens.  Moreover,  consulting  HIV
physicians  specialized  in  HIV  care  and  travel  medicine  should  prescribe  an  adequate 
chemoprophylaxis  in  patients  travelling  towards  malaria  endemic  areas  and  pay  attention  on 
interactions between antiretrovirals and antimalarial prophylaxis drugs in order to prevent clinical 
complications of this co-infection.
This review aims to evaluate the availa
in adults providing a critical comprehensive review of nowadays knowledge.
Introduction. Malaria  is  one  of  the  most  important 
causes of morbidity and mortality in tropical regions, 
especially in sub-Saharan Africa and South
The disease is caused by an infection sustained by a 
parasite  of  the  genus  Plasmodium;  five  species  of 
Plasmodium (P.  falciparum,  P.  vivax,  P.  ovale,  P. 
malariae  and P.  knowlesi)  can  infect  human  and 
among these species, P. falciparum infection may be 
fatal.
2
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Malaria  and  HIV/AIDS  are  among  the  principal  causes  of  morbidity  and  mortality 
resource-limited  settings such  as  sub-Saharan  Africa
international community’s efforts to reduce incidence and prevalence of these diseas
a global public health problem. Clinical manifestations of malaria may be more severe in HIV 
infected patients, which have higher risks of severe malaria and malaria related death. Co
pregnant women, children and international travelers from non-malaria endemic countries are at 
higher risk of clinical complications. However, there is a paucity and conflicting data regarding 
infection,  particularly  on  how  HIV  infection  can  modify  the  response  to 
and  about  drug-interactions  between  antiretroviral  agents  and  artemisinin
based  combined  regimens.  Moreover,  consulting  HIV-infected  international  travelers  and 
physicians  specialized  in  HIV  care  and  travel  medicine  should  prescribe  an  adequate 
laxis  in  patients  travelling  towards  malaria  endemic  areas  and  pay  attention  on 
interactions between antiretrovirals and antimalarial prophylaxis drugs in order to prevent clinical 
This review aims to evaluate the available international literature on malaria and HIV co
in adults providing a critical comprehensive review of nowadays knowledge.
the  most  important 
causes of morbidity and mortality in tropical regions, 
Saharan Africa and South-East Asia.
1
The disease is caused by an infection sustained by a 
;  five  species  of 
m,  P.  vivax,  P.  ovale,  P. 
)  can  infect  human  and 
infection may be 
According to the World Malaria Report 2010
were 225 million cases of malaria and an estimated 781 
000 deaths in 2009. Most deaths occur among children 
living in Africa where a child dies every 45 seconds for 
malaria  and  this  disease  accounts  for  approximately 
20% of all childhood deaths.
Human  Immunodeficiency  Virus  (HIV)  is  a 
retrovirus  that  can  infect  immune  competen
causing  an  impairment  of  host  defense.  After  the 
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Malaria  and  HIV/AIDS  are  among  the  principal  causes  of  morbidity  and  mortality 
Saharan  Africa.  Despite  the 
international community’s efforts to reduce incidence and prevalence of these diseases, they remain 
a global public health problem. Clinical manifestations of malaria may be more severe in HIV 
infected patients, which have higher risks of severe malaria and malaria related death. Co-infected 
malaria endemic countries are at 
higher risk of clinical complications. However, there is a paucity and conflicting data regarding 
infection,  particularly  on  how  HIV  infection  can  modify  the  response  to 
interactions  between  antiretroviral  agents  and  artemisinin-
infected  international  travelers  and 
physicians  specialized  in  HIV  care  and  travel  medicine  should  prescribe  an  adequate 
laxis  in  patients  travelling  towards  malaria  endemic  areas  and  pay  attention  on 
interactions between antiretrovirals and antimalarial prophylaxis drugs in order to prevent clinical 
ble international literature on malaria and HIV co-infection 
in adults providing a critical comprehensive review of nowadays knowledge.
World Malaria Report 2010, there 
were 225 million cases of malaria and an estimated 781 
. Most deaths occur among children 
living in Africa where a child dies every 45 seconds for 
malaria  and  this  disease  accounts  for  approximately 
20% of all childhood deaths.
2
Human  Immunodeficiency  Virus  (HIV)  is  a 
retrovirus  that  can  infect  immune  competent  cells 
causing  an  impairment  of  host  defense.  After  the Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
introduction of  Highly  Active  Antiretroviral Therapy 
(HAART) in 1996, the epidemiology of HIV infection 
has  changed  and  clinical  evolution  turned  a  fatal 
disease  in  a  treatable  chronic  infection  with an 
improved quality of life and a reduction of morbidity 
and  mortality.
3 However,  nowadays  there  are  still 
alarming  figures  of  HIV/AIDS  infected  people 
worldwide: in 2010 it was estimated that people living 
with HIV infection were 34 million, 2.7 million people 
became newly infected  in  the  same year  and  AIDS-
related  deaths  were  1.8  million,  including  250  000 
children. Two  thirds  of HIV  infections  were in  sub-
Saharan Africa.
4 Therefore, there is a critical overlap 
between the two infections especially in sub-Saharan 
Africa resulting in particular concern for Public Health. 
The  increasing  number  of  people  potentially  co-
infected makes this topic of particular interest in order 
to correctly understand and control both infections and 
their particular interactions.
5
Clinical  presentation  of  malaria  in  HIV-infected 
people, even if partially immune to Plasmodium, may 
be more severe and, although malaria is not the main 
cause  of  death  among  HIV-infected  patients,
6 in  a 
systematic review of HIV-1 infection in Africa, malaria 
was  identified  as  the  third  cause  of  HIV-related 
morbidity.
7 This is more evident in special populations 
such as HIV-infected pregnant women,
8 as well as in 
adults  male  and  female  with  an  severely  impaired 
immune system
9 and in HIV-infected travelers.
10
Moreover,  despite  the  importance  of  proper 
treatments  against both  infections,  there  is  a  lack  of 
data  regarding  treatment  issue:  conflicting  data  are 
presented in literature about the effects of antimalarial 
drugs  (for  treatment  and  chemoprophylaxis)  on 
antiretroviral  agents  and  vice-versa and  data  about 
drug-interactions  between  antimalarial  (especially 
artemisinin-based  combinated  treatment  – ACT)  and 
antiretroviral drugs are missing.
11
Purpose  of  this  article  is  to  review  the  current 
knowledge on  clinical  tools  of  malaria and HIV  co-
infection in adults, focusing on pregnant women and 
international travellers, and to explore the interactions 
between  antiretrovirals  and  antimalarial  drugs,
suggesting future research priorities.
Interactions  Between  Malaria  and  HIV  Infection. 
Sub-Saharan Africa represents the region most heavily 
affected by both malaria and HIV. In this setting, the 
overlap of these two infections is common and it would 
be important to understand their interactions and their 
correct  management  in  order  to  limit  their  clinical 
burden.
12
The  influences  between  HIV  and  malaria  are 
bidirectional  and  synergistic,
5,13 and  the  negative 
effects of this co-infection, for the most part, seems to 
be due to immunological interactions: HIV replication 
impairs  immune  system  and  consequently  malaria 
control;
14 on  the  other  hand,  malaria  itself  enhances 
HIV  replication  by  cytokines  release  and  T-cell 
activation.
15
Looking at HIV-infection during malaria, it seems 
that  HIV  infection  worsens  the  capability  to  control 
parasitaemia  because  of  deterioration  of  immune 
responses to malaria parasites; several studies reported 
an association between HIV infection and higher levels 
of malaria parasitaemia. Whitworth et al. demonstrated 
that higher levels of parasitaemia were more frequently 
detected  among  HIV-positive  patients  compared  to 
those  mono-infected (11.8%  vs  6.3%,  p<0.0001), 
moreover  they  found  an  association  between  lower 
CD4+ T-cell count and higher levels of parasitaemia 
(p=0.0076), and lower CD4+ T-cell count and risk of 
clinical  manifestations  of  malaria.
14 French  et  al. 
confirmed this data finding that incidence rates of P. 
falciparum malarial fever were indirectly proportional 
to CD4+ T-cell count,
16 while Patnaik and colleagues 
supported the relationship between CD4+ T cell count 
and malaria parasitaemia in HIV-seropositive subjects 
finding  an  adjusted  hazard  ratio  of  1.8  for a  first 
parasitaemia  episode,  and  of  2.5  for  a  second 
parasitaemia episode.
17
The  intensity  of  malaria  transmission  and  the 
population’s level of acquired immunity may influence 
the  clinical  impact  of  malaria.  Two  major  levels  of 
malaria  endemicity  are  described:  i)  areas  of  high 
(stable)  malaria  transmission,  where  most  of  adults 
have  developed  enough  immunity  that  lead  to  poor 
clinical manifestations of malaria infection and where 
the  reported  incidence  of  malaria  was  ≥  1/1000  per 
year  in  2009;
4 ii)  areas  of  low  (unstable)  malaria 
transmission,  where  people  have  not  acquired  a 
significant  level  of  immunity  with  consequent  high 
level of clinical appearance of the infection. In these 
areas the transmission is more often seasonal and the 
reported incidence of malaria was < 1/1000 population 
per  year  in  2009.
4 Severe  malaria  and  consequent 
deaths  seem  to  be  higher  in unstable  transmission 
areas,
18 but  some  studies  have  demonstrated  an 
increase  in  malaria  incidence  in  regions  of  stable 
malaria transmission when it is associated with HIV-
infection.
14,16 Whitworth’s  study,  previously 
mentioned, was conducted in malaria endemic regions 
in  Uganda,  and  demonstrated  that  risk  of  clinical 
malaria was 4.0% among HIV-1-positive patients and 
1.9%  among  HIV-negative  patients;
14 also  French’s 
trial  was  conducted  among  people  from  Uganda. 
However,  some  studies  show  conflicting  data  not 
describing an increase in severity of malaria from areas 
of stable transmission. Cohen et al. found a statistical 
significant  correlation  (p=0.003)  between  severe Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
malaria and HIV infection among people nonimmune 
to  malaria, instead this association was not found in 
semi-immune  patients  (p=0.284).
9 Other  studies
19,20
concluded  for  the  lack  of  association  between  HIV 
infection and malaria outcomes, but they suffer form 
some  limitations:  patients  analysed  were 
predominantly  children
19 or  only  children
20 that,  for 
their  characteristic  anti-parasite  immunity  are  not 
comparable with adult population.
16
HIV-positive patients with malaria presented higher 
incidence of anaemia,
21 as demonstrated in a study in 
which co-infected patients showed lower haemoglobin 
levels compared to subjects with only malaria;
22 in fact, 
both malaria and HIV may cause anaemia, as well as 
some  drugs  (e.g.  zidovudine  – AZT) used for  HIV 
treatment.
23
Looking  now  at  the  consequences  of  malaria 
infection on HIV disease progression, several studies 
showed an increased HIV-RNA replication in patients 
with malaria. Hoffman et al found 7-fold higher levels 
of HIV-1 RNA in patients with malaria than in those 
with  only  HIV  infection  (p  <0.0001)
24 and  another 
study  showed  that  HIV-1  RNA  concentrations  were 
even 10-fold higher in co-infected patients in respect of 
HIV  mono-infected  patients.
5 In a  trial  conducted in 
Malawi, Kublin and colleagues demonstrated that viral 
load returned at baseline levels only after 8-9 weeks of 
antimalarial therapy.
25 Epidemiological implications of 
this aspect are that higher HIV-transmission rates are 
present in co-infected patients.
26
Based  on  data  presented,  we  suggest  a  strict 
monitoring of co-infected patients in order to improve 
the outcomes of these two infections, in particular for 
people most at risk of complications, such as pregnant 
women,  in  particular  in  stable  malaria  transmission 
areas  where  adults’  parasitaemia  values  are  often 
below threshold of detection.
Malaria and HIV Co-Infection in Pregnant Women. 
It is estimated that each year about 24 million pregnant 
women  are  infected  by  P.  falciparum,  especially  in 
sub-Saharan Africa
8 and about 1 million per year are 
co-infected  with  HIV.
27 It  is  known  that  co-infected 
pregnant  women  are  particularly  at  risk  of 
complications  due  to  these  two  infections;  in  fact, 
women during pregnancy are more likely susceptible to 
malaria  disease  than  non-pregnant  women,
28 and  a 
down regulation of the adaptive immune response was 
observed  with  a  consequent  enhanced  placental 
invasion.
29 High  levels  of  parasitaemia  and  chronic 
parasite  infection  in  placental  blood  can  lead  to 
consumption  of  nutritive  blood  substances,
30 to  a 
worsening of perinatal outcomes and to increased rates 
of  maternal  morbidity.
31 In  this  context  co-infection 
with  HIV  represents  a  further  immune  system 
impairment,  which  can  be  a  concurrent  cause  of 
uneffectiveness in parasitaemia control.
12
Consequences of this co-infection are described in 
both directions: HIV may promote more severe malaria 
clinical manifestations and, on the other hand, malaria 
can  favours  HIV  RNA  replication  threatening 
antiretroviral treatment effectiveness.
32
In  co-infected  pregnant  women,  all  the  adverse 
pregnancy outcomes are present. HIV impaired malaria 
outcomes  inducing  chronic  parasitaemia,  higher 
parasite densities and fever, reflecting in more severe 
clinical  malaria  manifestations.
12,33 In  a  study 
conducted  by  ter  Kuile  and  colleagues  data  from 
several works were summarized: the risk ratio [RR] of 
malaria parasitaemia in co-infected women were 1.58 
during pregnancy, 1.66 at the time of delivery and 1.66 
in the placenta in respect of HIV-uninfected women.
34
There  is  also  an  higher  risk  of  postpartum  maternal 
anaemia:  Ayisi  et  al.  found  that  the  probability  to 
manifest this clinical condition  was more than twice 
higher in  women co-infected than in  HIV-uninfected 
women.
35 Malaria and HIV infections were associated 
with  several  negative  outcomes  in  newborns  to  co-
infected  mothers.  Ticconi  et  al.  demonstrated  an 
association between co-infection and an increased risk 
of  stillbirth  (OR  =  4.74,  95%  CI:  1.34-16.78)  and 
preterm delivery (OR = 4.10, 95% CI: 2.17-7.75). The 
two  infections,  instead,  resulted  independently 
associated with an increased risk of low birth weight 
(malaria: OR = 10.09, 95% CI: 6.50-15.65; HIV: OR = 
3.16, 95% CI: 1.80-5.54) and foetal growth retardation 
(malaria: OR = 3.98, 95% CI: 2.51-6.30; HIV: OR = 
4.07, 95% CI: 2.40-6.92) compared to HIV-uninfected 
women.
36 Low birth weight (LBW) prevalence appear 
to be higher in co-infected women (P=0.001) compared 
to  HIV  mono-infected  women  (p=0.09)  and  malaria 
infected alone (P=0.006). In addition infant mortality 
seems  to  be  higher  in  infants  born  to  co-infected 
women.  A  study  conducted  in  Malawi  reported 
significantly  higher  mortality  rates  among  children 
born  to  HIV-seropositive  compared  to  HIV-
seronegative women, and in the multivariate model the 
risk of neonatal mortality was 4.5 greater in co-infected 
mother  compared  to  mother  with  only  placental 
malaria  and  2.7-7.7  greater  in  HIV  mono-infected 
mothers.
37
As  previously  said,  malaria  promotes  HIV  RNA 
replication: a study showed that women had about 2-
fold  increase  in  HIV-1-RNA  both  in  peripheral  and 
placental blood, with a consequent higher possibility of 
mother-to-child  transmission  of  HIV,
38 even  if,  at 
present, a clear association between placental malaria 
and an increase of mother-to-child transmission of HIV 
infection still remains uncertain.
12
An  appropriate  control  of  both  infections  is  a Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
priority  either  for  women  and  for  their  infants.  The 
main  recommendations  are:  a  prompt  HAART 
initiation in pregnant women as soon as the eligibility 
criteria  are  met,  or  an  effective  antiretroviral 
prophylaxis  if  criteria  for  initiating  ART  are  not 
present,  according  to  World  Health  Organization 
(WHO)  specific  guidelines.
39 Therefore  a  proper 
prophylaxis with co-trimoxazole after the first trimester 
of  pregnancy  seems  to  prevent  both  opportunistic 
infections and malaria.
34
Malaria  in  HIV-Infected  International  Travellers. 
According to the World Tourism Organization (WTO), 
an  increasing  number  of  international  travellers has 
been reported, from 50 million/year after second World 
War to 980 million/year during 2011.
40 Approximately 
80 million persons from industrialized nations travel to 
the tropical world each year.
41 Imported malaria mostly 
occurs in tourists and migrants travelling to their origin 
countries  to  visit  friends  and  relatives  (VFR)
42 but 
higher  rates  of  malaria  infection  have  been  reported 
also among HIV-infected people.
43
This is mainly due to the introduction of HAART 
and  the  improved  quality  of  life  allowed  a  steady 
increase of international travels, especially to tropical 
areas.
44 A recent report showed that international travel 
among HIV-infected people was associated with poor 
adherence  to  antiretroviral  therapy,  risky  sexual 
practices  and  risky  exposure to  travel-related 
diseases.
45 Although  any  travel-related  disease  may 
have  more  severe  clinical  manifestations  in  HIV 
positive  travellers  compared  to  HIV-uninfected 
persons, malaria is certainly one of the most dangerous 
conditions;
46 therefore HIV-infected patients should be 
more aware of the necessity for medical counsel prior 
to travel
47,48 particularly to prevent malaria infection.
Several cases of imported malaria, as well severe 
cases with fatal outcome, have been reported;
49,50,51,52
however clinical presentation is often similar to HIV-
negative patients as recently reported in a retrospective 
study  conducted  in  Spain.
53 These  data  suggest  that 
more  caution  should  be  taken  during  the  pre-travel 
counselling.
WHO  recommends  a  viro-immunological 
parameters  check  (CD4+  T  cell  count  and  HIV 
viraemia  at  least)  and  a  clinical  examination  before 
travelling.
54 Obviously,  for  HIV-infected  pregnant 
women and young children travel should be avoided if 
not  strictly  necessary  as  they  have  higher  risks  of 
severe malaria clinical manifestations.
Then, physicians involved in HIV care as well as in 
travel medicine should consider several factors in pre-
travel counselling for HIV-infected travellers such as 
reason for travel (tourism, VFR, business etc.), travel 
risk  (pre-arranged  or  organized  travel),  travel 
destination, season and malarial epidemic cycle as well 
as Plasmodium drug sensitivity in the specific area;
10
moreover  HIV-infected  people  travelling  to  malaria 
endemic-areas need to start a correct chemoprophylaxis
regimen  before  their  travel  and  counsellors  should 
consider  possible  drug  interactions  between 
antiretroviral and antimalarial drugs.
10
Therefore the importance of behavioral preventive 
measures  (bed  nets,  repellents,  etc.),  adequate 
chemoprophylaxis  and, in  selected  circumstances, 
stand-by  emergency  treatment  in  case  of  evocative 
symptoms should be strongly recommended.
Effects  of  Co-Trimoxazole  Prophylaxis  and 
Antiretroviral  Therapy  on  Malaria.  According  to 
major  International  Guidelines
55,56 HAART  regimens 
should  contain  at  least  three  active  drugs  from  two 
different  classes,  usually  2  nucleos(t)ide  reverse 
transcriptase inhibitors (NRTIs) accompanied with an 
anchor drug which is either a non-nucleoside reverse 
transcriptase inhibitors (NNRTI) or a protease inhibitor 
(PI) with a low-dose of ritonavir (RTV) as “booster”. 
Sustained  virological  suppression  and  CD4+  T  cell 
count recovery is the main objective of HAART.
55 In 
HIV-infected patients, daily co-trimoxazole should to 
be  prescribed  as  prophylaxis  against  major 
opportunistic  infections  when  CD4+ T  cells  are  less 
than 200/µl;
57 however several findings demonstrated 
that daily co-trimoxazole prescription may reduce the 
occurrence of parasitaemia
58 and clinical malaria either
in adults and in children.
59,60,61
For example, Mermin J and colleagues
58 found that 
among HIV-infected children the use of co-trimoxazole 
prophylaxis and insecticide-treated  nets might reduce 
the prevalence of clinical malaria by 97% versus the 
reduction  of  43%  with  nets  alone.  Therefore  co-
trimoxazole  prescription  in  immunocompromised 
patients, in addition at insecticide-treated nets, seems 
to be an effective strategy to prevent malaria. However, 
cross  resistance  between  co-trimoxazole  and 
sulfadoxine-pyrimethamine  (SP)  has  been  reported,
62
therefore widely use of co-trimoxazole  may promote 
specific  SP  resistance; some  studies  did  not  find  SP 
related  resistances  despite  co-trimoxazole 
prescription,
63,64 while others found that co-trimoxazole
prophylaxis  was  effective  despite  antifolate 
resistance.
60
Therefore  some  authors  suggested  that  a 
continuation  of  prophylaxis  with  co-trimoxazole  in 
malaria endemic areas is beneficial even when patients 
have  been  immune  restored.
11 Antiretroviral  therapy 
may be effective against malaria infection: Mermin J et 
al
65 in a prospective cohort study found that HAART 
containing  NRTIs  when  co-administrated  with  co-
trimoxazole  decrease  malaria  clinical  presentation  in Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
respect of co-trimoxazole alone; in order to provide an 
explanation  on  the  possible  antimalarial  activity  of 
NRTIs,  authors  hypothesized  that  HAART  probably 
reduced  the  frequency  of  malaria  by  improving 
immune function rather than by a direct antimalarial 
effect.  A  delayed  P.  falciparum clearance  in  HIV-
infected  patients  treated  with  artemisinin-based 
regimens has been reported
66 suggesting that immune 
defences  of  HIV-infected  people  may  affect 
effectiveness  of  antimalarial  treatment.  Other  studies 
evaluating  impact  of  PIs  are  ongoing  (e.g. 
NCT00719602) but available studies “in vitro” showed 
that the PIs lopinavir, saquinavir, indinavir, atazanavir 
ritonavir  have  direct  effect  on  inhibition  of  P. 
falciparum,  at  concentration used  in  clinical 
practice.
67,68 Anyway,  antiretroviral  treatment  maybe 
effective  against  P.  falciparum and  may  reduce 
malarial clinical manifestation, but, in order to better 
clarify  this  hypothesis,  its  underlying  biological 
mechanisms  and  the  role  of  antiretroviral  drugs  or 
classes need further investigations.
Interactions  Between  Antiretrovirals  and 
Antimalarial Agents:
Antiretrovirals  and  antimalarial  drugs  (treatment). 
Pharmacological  interactions  between  antiretroviral 
and antimalarial drugs has been previously extensively 
reviewed,
69,13 however  the  knowledge  about  this 
critical topic is still debated and data reported are not 
definitive, particularly due to either the paucity of data 
about newer drugs and classes of antiretroviral agents 
and the absence of specific guidelines. Moreover the 
relevance  of  “in  vitro”  studies  in  common  clinical 
practice is controversial. According to WHO, first-line 
treatment  for  uncomplicated  malaria  in  high-
endemicity areas  consists of  a  combination of  either 
artemether plus lumefantrine or artesunate plus one of 
the  following  drugs:  amodiaquine,  mefloquine,  or 
sulfadoxine–pyrimethamine,  or  dihydroartemisinin–
piperaquine.
1 Interactions  between  amodiaquine  and 
efavirenz  has  been  reported  reflecting  in  higher 
amodiquine  concentrations;
70 these  evidences  may 
have a clinical impact, as a significant number of HIV-
infected  patients  in  sub-Saharan  Africa  receive  an 
efavirenz-based treatment
57 and WHO contraindicates 
this co-administration;
27 furthermore, given that these 
drugs  are  both  potentially  hepatotoxic
71,72 patients 
prescribing  this  combination  have  to  be  strictly 
monitored. Finally, we know that quinine, halofantrine, 
and lumefantrine are all antimalarial drugs metabolized 
through the cytochrome P-450 enzyme system;
73,74 so 
that, these drugs may potentially interact with the non-
nucleoside  reverse  transcriptase  inhibitors  (NNRTIs) 
resulting in reduced bioavailability of the antimalarial 
drugs.
75 Recently, a cross-sectional study in HIV and 
malaria  co-infected  adults  showed  significant 
pharmacokinetic  interactions  among  nevirapine, 
artemether  and  dihydroartemisinin:  these  interactions 
maybe  increase  the  risk  of  treatment  failure  of  both 
infections  and  the  risk  for  development  of  drug 
resistance.
76 Drug-interactions  with  PIs, that  are  also 
metabolized  through  the  hepatic  cytochrome  P-450 
enzyme  system,  and  enzyme  inhibition  by  ritonavir 
may on the contrary increase serum concentrations of 
these antimalarials.
77 Despite this study, performed in 
healthy  volunteers,  ritonavir  might  boost  the 
bioavailability  of  either  PIs  and  antimalarial  drugs, 
however  this  altered  pharmacokinetics  do  not  seems 
clinically  relevant.  By  contrast,  a  recent  study 
confirmed  that  LPV/r-based  HAART  significantly 
increases lumefantrine exposure without an increase in 
adverse  effects.  Artemether  and  dihydroartemisinin 
concentrations  were  also  significantly  increased  by 
ritonavir  boosted  lopinavir-based  treatment,  but  to  a 
lesser extent.
78 Data from randomized-controlled trials 
will  be  highly  valuable  in  evaluating  the  clinical 
significance of all these interactions.
Most of potential clinically significant interactions 
between  antimalarial  and  antiretrovirals  drugs  are 
showed in Table 1.
Malaria  chemoprophylaxis  in  HIV  infected  subjects. 
Despite  several  reports  and  reviews  on  malaria  and 
HIV  co-infection,  few  data  are  present  in  literature 
about  the  use  of  malaria  chemoprophylaxis  in  HIV 
infected  travellers.
57 Mefloquine  reduces  some 
ritonavir boosted  protease  inhibitors  levels  and 
mefloquine  plasma  levels  could  be  reduced  by 
efavirenz  and  nevirapine,  but  these  data  are  from 
patients who received mefloquine as treatment, little is 
known  about  its  use  in  chemoprophylactic  regimen. 
Atovaquone/proguanil  levels  could  be  reduced  by 
indinavir, as well as lopinavir, atazanavir, ritonavir and 
efavirenz;
79 moreover,  atovaquone/proguanil  could 
reduce indinavir levels and increase zidovudine levels 
causing  hematological  troubles.
80 No  significant  data 
are  available on doxycycline interactions.
81 All these 
considerations  should  be  taken  into  account  before 
starting  chemoprophylaxis  in  HIV  infected  travelers 
taking HAART, and drugs dosages should be arranged 
in  order  to  avoid  drug  interactions.  If 
chemoprophylaxis  is  not  administered, 
atovaquone/proguanil  might  be  a  suitable  stand-by 
emergency treatment (SBET) option for HIV-infected 
subjects  receiving  NNRTI-based  regimens,  while 
mefloquine could be considered as SBET drug in those 
prescribing PI-based HAART.
82
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Table 1: Potential interactions between antimalarial and antiretroviral drugs.
Antimalarial drugs Antiretroviral drugs Potential interactions
Quinine EFV, NVP Reduced quinine concentrations
Quinine PI Reduced quinine concentrations
Atovaquone/Proguanil RTV, LPV/r, ATV/r, IDV, 
EFV Reduced atovaquone/proguanil concentrations
Atovaquone/Proguanil IDV Reduced IDV concentrations
Atovaquone/Proguanil AZT Increased AZT concentrations
Increased risk for anaemia
Mefloquine RTV Reduced RTV concentrations
Mefloquine EFV, NVP Reduced mefloquine concentrations
Lumefantrine PI Increased lumefantrine concentrations
Prolongation of QT interval
Lumefantrine NVP, EFV, DLV Reduced lumefantrine concentrations
Prolongation of QT interval
Halofantrine PI Increased halofantrine concentrations
Prolongation of QT interval
Halofantrine NVP, EFV, DLV Reduced halofantrine concentrations
Prolongation of QT interval
Amodiaquine + artesunate EFV Increased amodiaquine concentrations
Increased transaminase levels
Chloroquine RTV Alteration of antimalarial drug metabolism
Pyrimethamine RTV Alteration of antimalarial drug metabolism
Sulfadoxine-pyrimethamine RTV Alteration of antimalarial drug metabolism
Sulfadoxine-pyrimethamine NVP Possible adverse cutaneous or hepatic reactions
Sulfadoxine-pyrimethamine AZT Increased risk for anaemia
Sulfadoxine-pyrimethamine Co-trimoxazole Increased risk of severe adverse cutaneous or hepatic 
reactions
Artemisinin PI Alteration of artemisinin metabolism
Dapsone SQV Alteration of dapsone metabolism
Modified by Flateau C, Lancet Infect Dis, 2011; Skinner-Adams TS, Trends Parasitol, 2008; Khoo S, AIDS, 2005.
11,13,69
EFV: efavirenz; NVP: nevirapine; PI: protease inhibitors; RTV: ritonavir; LPV: lopinavir boosted by ritonavir; ATV/r: atazanavir boosted by 
ritonavir; IDV: indinavir; AZT: zidovudine; DLV: delavirdine; SQV: saquinavir.
important infectious diseases worldwide, particularly in
sub-Saharan Africa: their overlapping epidemiology as 
well  their  impact  in  clinical  practice  needs  to  be 
continuously updated.
HIV-infected  adults,  especially  if  international 
travelers,  even  with  a  restored  immunity,  are  more 
likely to have severe clinical manifestations of malaria 
compared  to  travellers  without  HIV  infection. 
Moreover co-infection in pregnant women contributes 
to develop clinical malaria in women, maternal severe 
anaemia, grater rates of stillbirth and preterm delivery, 
low birth weight, foetal grow retardation and increased 
risk of infant mortality.
The  wider  implementation  of  co-trimoxazole 
prophylaxis and antiretroviral therapy could change the 
impact of malaria in HIV-infected patients. 
The benefits of the continuation of co-trimoxazole 
prophylaxis to prevent malaria, the antimalarial effects 
of several antiretroviral agents, as well the interactions 
between antiretroviral and antimalarial drugs, need to 
be further investigated. The proper malaria prophylaxis 
and  treatment  in  HIV-infected  pregnant  women  also 
needs to be defined. Several clinical trials are ongoing 
to address several of these opened questions: the results 
of these trials are needed to create specific guidelines 
for the prevention and management of malaria and HIV 
co-infection and to help clinicians involved in travel 
medicine as well in HIV care.
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